【藥品庫存】 單株抗體本院備有庫存，請參閱說明書，本品需先下載檢核表及病人同意書，填寫完畢後交給感染控制部，經諮詢區管指揮官同意後，藥劑部將開檔供醫師醫囑。

Coronavirus disease 2019 (COVID-19), mild to moderate

Antiviral Agent; Monoclonal Antibody
Casirivimab and imdevimab are recombinant human (IgG1κ and IgG1λ, respectively) monoclonal antibodies to the spike protein of SARS-CoV-2. Casirivimab and imdevimab bind to nonoverlapping epitopes of the spike protein receptor binding domain, blocking attachment to the human ACE2 receptor.

Half-life elimination: Casirivimab: 31.8 ± 8.35 days; Imdevimab: 26.9 ± 6.8 days
Time to peak: Casirivimab: 8 days (range: 4 to 87 days); Imdevimab: 7 days (range: 4 to 15 days)

Casirivimab and imdevimab are currently available under FDA emergency use authorization (EUA) for the treatment of COVID-19. Reproductive toxicity studies have not been conducted

It is not known if casirivimab or imdevimab are present in breast milk; however, casirivimab and imdevimab are humanized monoclonal antibodies (IgG1); maternal IgG is present in breast milk

Injection site reaction, nausea, vomit, infusion related reaction, anaphylaxis, angioedema

COVID-19, weight over 40kg: (IV preferred, SUBQ alternative) Casirivimab 600 mg and imdevimab 600 mg as a single dose; administer as soon as possible after a positive SARS-CoV-2 test and within 10 days of symptom onset

Emergency use authorization from the FDA is based on likelihood of similar exposures in patients >12 years of age weighing >40 kg

No dosage adjustment recommended

There are no dosage adjustments provided (has not been studied)